Please login to the form below

Not currently logged in
Email:
Password:

Ironwood promotes Dr Mark Currie

He moves up to chief scientific officer at the US pharma company

Ironwood Pharmaceuticals Dr Mark CurrieIronwood Pharmaceuticals has promoted Dr Mark Currie to senior vice president, chief scientific officer and president of R&D.

He previously led the Cambridge, Massachusetts-based company's R&D efforts, having joined the firm in 2002.

Prior to this he directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor and before that served as director of arthritis and inflammation at Monsanto Company.

Ironwood's CEO Peter Hecht said: “Mark's outstanding contributions to Ironwood, including his expertise, leadership and superb judgment, are invaluable as we move our R&D efforts forward, growing our active pipeline and expanding our development efforts globally on behalf of our shareholders and the patients we aim to serve.”

Currie's academic research on the guanylate cyclase-C (GC-C) pathway laid the foundation for the discovery by Ironwood scientists of linaclotide.

Linaclotide was approved as a treatment for irritable bowel syndrome last year by regulators in Europe, where the drug is marketed as Constella by Almirall.

19th February 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

AI and genomics: a revolution in drug discovery and development
...
Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....

Infographics